SOFOSBUVIR-VELPATASVIR IN CHRONIC HEPATITIS C IN PATIENTS WITH CHRONIC KIDNEY DISEASE

  • AADIL ASHRAF GASTROENTEROLOGY,SKIMS
  • ALTAF SHAH
Keywords: SVR 12, SOFOSBUVIR, VELPATASVIR

Abstract

BACKGROUND: India is witnessing high hepatitis C virus (HCV) infection burden in patients of chronic kidney disease. Due to nonavailability of costly recommended directly acting antiviral drugs in ESRD, a pan-genotypic combination of Sofosbuvir-Velpatasvir can become an economical option. Data regarding treatment with this combination is scarce. Ours is only third and the largest study from Indian subcontinent.

OBJECTIVES: The study was undertaken to assess the efficacy, safety and side effect profile of Sofosbuvir-Velpatasvir in CKD patients.

PARTICIPANTS: Included both in and outpatient treatment naïve anti-HCV positive CKD patients after proper informed consent.

Methodology: The study was conducted from 1st September 2018 till February 2021. Patients were grouped into three categories on basis of GFR. All the patients were evaluated for liver disease. All the patients received open label combination of sofosbuvir and velpatasvir (400 mg/100 mg). The primary and secondary end-point was to assess sustained virological response [SVR12] and safety profile respectively.

Results: 195 patients were included in the study. In group A [ESRD and on hemodialysis] (162 patients),160(98.7%) achieved viral clearance 12 weeks after treatment (SVR12). Remaining 2 patients expired. Significant difference was seen in pre and post treatment serum bilirubin and ALT levels. No significant difference was found in pre and post treatment Sr albumin, creatinine and other parameters. The adverse effects noticed were nausea(20%), vomiting(18%), headache(10%), weakness(7%). In group B and C[GFR>15ml/min/1.73m2] ,100 % of patients achieved SVR12. Other findings were comparable to group A.

Conclusion: Our study showed excellent efficacy with the safety profile of this drug combination across all CKD stages.

Downloads

Download data is not yet available.
Published
2021-05-12
How to Cite
1.
ASHRAF A, SHAH A. SOFOSBUVIR-VELPATASVIR IN CHRONIC HEPATITIS C IN PATIENTS WITH CHRONIC KIDNEY DISEASE. jms [Internet]. 2021May12 [cited 2026Nov.18];24(Suppl 1). Available from: https://old.jmsskims.org/index.php/jms/article/view/1021